DexCom (DXCM) to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) is scheduled to announce its earnings results after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $0.27 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the company earned $0.34 EPS. The business’s quarterly revenue was up 26.9% compared to the same quarter last year. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

DXCM stock opened at $131.52 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a one year low of $74.75 and a one year high of $142.00. The stock has a market cap of $50.70 billion, a PE ratio of 100.40, a P/E/G ratio of 2.25 and a beta of 1.20. The firm has a 50 day simple moving average of $129.81 and a two-hundred day simple moving average of $117.38.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DXCM. UBS Group upped their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Finally, Raymond James upped their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.